CYT-108
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CYT-108, covering 2025-12-26 to 2025-12-26. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee [Phase 1]